AstraZeneca (LON:AZN) Stock Crosses Above 200 Day Moving Average – Time to Sell?
AstraZeneca PLC (LON:AZN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as ...
Zawya1d
Over 67 million screenings – AstraZeneca’s ‘Healthy Heart Africa’ celebrates 10 years of transforming Noncommunicable Disease (NCD) care
AstraZeneca’s ( www.AstraZeneca.com) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th ...
cambridgeindependent2d
AstraZeneca revenues rise to $54bn as it enters ‘unprecedented’ period for company
AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...
Sumitomo Mitsui Trust Group Inc. Has $5.58 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)
Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...
Astrazeneca Pharma gains after Q3 PAT soars to Rs 55 cr
Astrazeneca Pharma India advanced 1.21% to Rs 7557.05 after the company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24.
Zawya4d
PHRMAG appoints new Executive Committee for 2025–2027
PHRMAG represents 29 leading global biopharmaceutical research companies in the region. Dedicated to advancing innovation and ...
FierceBiotech3d
Biogen enlists Royalty for pursuit of lupus crown, securing $250M to fund phase 3 program
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
The NHS ‘double whammy’ undermining a £108bn British industry
Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...
AstraZeneca PLC (AZN): Among the Best International Dividend Stocks to Buy Now
We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...
ascopubs.org5d
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...